武田制药2025财年第二财季实现净利润8.60亿美元,同比增加40.75%

市场透视
Aug 04

8月4日,武田制药(TAK.US)公布财报,公告显示公司2025财年第二财季净利润为8.60亿美元,同比增加40.75%;其中营业收入为76.59亿美元,同比减少1.20%,每股基本收益为0.27美元。从资产负债表来看,武田制药(TAK.US)总负债494.19亿美元,其中短期债务25.69亿美元,资产负债比为1.97,流动比率为1.16。机构评级:截至2025年8月4日,当前有14家机构对...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10